INDIANAPOLIS – Eli Lilly (NYSE:LLY) announced a fourth quarter dividend of $1.30 per share on its outstanding common stock. The declared dividend will be paid on December 10, 2024 to shareholders registered in the shareholder register as of November 15, 2024.
With a history spanning nearly 150 years, the pharmaceutical giant is known for its contributions to medicine, translating scientific discoveries into therapeutic solutions that improve lives around the world. Eli Lilly’s portfolio includes treatments that address health problems such as diabetes, obesity, Alzheimer’s disease, immune system disorders and various cancers. The company focuses on innovative clinical trials that reflect global diversity and works to make medicines accessible and affordable.
This dividend declaration follows Eli Lilly’s tradition of returning shareholder value and continues its quarterly dividend payments. Forward-looking statements regarding the Company’s expected dividend payments contain an acknowledgment of the risks and uncertainties inherent in pharmaceutical research, development and business strategies.
Investors are cautioned that actual results may differ materially due to these risks and uncertainties. Eli Lilly directs those seeking a more detailed understanding of these risks to its filings with the Securities and Exchange Commission, including Form 10-K and Form 10-Q.
Information regarding the dividend declaration is based on Eli Lilly’s press release statement.
In other recent news, Eli Lilly reported positive long-term results from a Phase 3 study of mirikizumab, a drug used to treat ulcerative colitis and Crohn’s disease. The pharmaceutical giant is also set to launch weight loss drug Mounjaro in Hong Kong, subject to government approval. Leerink Partners maintains an Outperform rating on Eli Lilly stock, indicating confidence in the company’s performance.
Eli Lilly’s EBGLYSS, a treatment for moderate to severe atopic dermatitis, has shown promising results in improving skin condition and reducing itching. The company also initiated legal action against Pivotal Peptides, MangoRx, and Genesis Lifestyle Medicine of Nevada for allegedly selling counterfeit versions of the weight loss drug Zepbound.
These are the latest developments regarding the company’s operations and products. Investors should note that these updates reflect the company’s continued progress and potential challenges. It is important to remember that this information is based on recent reports and is not a prediction of future results or performance.
InvestingPro Insights
Eli Lilly’s recent dividend declaration is consistent with its strong financial performance and commitment to shareholder value. According to InvestingPro data, the company’s revenue growth has been impressive, up 31.87% over the past 12 months as of Q2 2024. This strong growth is reflected in its market capitalization of $804.89 billion, making it a major player in the pharmaceutical industry.
The InvestingPro tip highlights Eli Lilly’s consistent dividend history, noting that the company has maintained its dividend for 54 consecutive years and raised its dividend for 9 consecutive years. This record highlights Eli Lilly’s financial stability and commitment to returning shareholder value, and is especially relevant with its recent dividend announcement.
The company’s strong financial strength is further evidenced by its gross margin of 80.75% and operating margin of 35.68% over the past 12 months. These metrics suggest that Eli Lilly is managing costs effectively while driving revenue growth, which supports its ability to maintain and potentially increase its dividend payments going forward.
It is worth noting that Eli Lilly is trading with a high P/E ratio of 109.65. This indicates investors’ confidence in the company’s future growth prospects. This assessment is consistent with the company’s focus on innovative therapies and a strong pipeline of potential therapeutics mentioned in the article.
For investors who want a more comprehensive analysis InvestingPro offers 17 additional tips on Eli Lilly to provide deeper insight into the company’s financial health and market position.
This article was translated with the help of artificial intelligence. Please refer to the Terms of Use for further details.
